Postes actifs de Johan Liwing
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
XNK Therapeutics AB
 XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Directeur Général | - | - |
CellProtect Nordic Pharmaceuticals AB
 CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | Directeur Général | - | - |
Historique de carrière de Johan Liwing
Statistiques
Internationale
| Suède | 3 |
Opérationnelle
| Chief Executive Officer | 2 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
XNK Therapeutics AB
XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Health Technology |
CellProtect Nordic Pharmaceuticals AB
CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | Health Technology |
- Bourse
- Insiders
- Johan Liwing
- Expérience
